Emmanuel Pakha-Ephraim

Introduction

Emmanuel Pakha-Ephraim is a biomedical scientist who stood on the Health and Care Professions Council (HCPC) register under number BS076762 and worked at NHS Blood and Transplant. On 17 September 2026, at the end of a substantive hearing that ran from 8 to 17 September 2026, a Health and Care Professions Tribunal Service (HCPTS) panel found his fitness to practise impaired by misconduct and dishonesty and struck him off the register. The case concerned failures in checking, documenting and reporting cell products and samples in 2023 and 2024, and dishonesty toward supervisors about altered paperwork and the verification of manually entered results. The panel found no insight or remediation and a real risk of repetition, with a risk of harm to patients, and imposed interim suspension to cover the appeal period before the substantive order takes effect.

Background Information

Pakha-Ephraim worked as a biomedical scientist at NHS Blood and Transplant, the health authority responsible for blood donation, testing and the supply of blood and cell products, registered with the HCPC under number BS076762. The published record does not state which laboratory or site he worked at, and it does not set out his registration history; this page does not guess at them. The failures found proved occurred in 2023 and 2024, in the handling of cell products and samples — work in which checking, documenting and reporting are safety-critical steps. The record shows an earlier regulatory interval: an interim suspension made on 22 October 2024 was confirmed by an Investigating Committee panel at an interim order review on 23 January 2026, months before the substantive hearing that decided the case.

The Controversy or Incident That Led to Their Cancellation

Adjudicated vs. alleged. The findings below come from an HCPTS panel determination, which decides allegations on the balance of probabilities. They are regulatory findings, not criminal convictions. The panel found some administrative errors were not misconduct individually, treating them as misconduct only as a collective pattern alongside the dishonesty findings.

The allegations concerned failures in checking, documenting and reporting cell products and samples at NHS Blood and Transplant in 2023 and 2024, and dishonesty toward supervisors about altered paperwork and verification of manually entered results. The panel proved the factual allegations and found misconduct and impairment on both the personal and public components. In its assessment, some administrative errors were not misconduct individually but collectively formed a serious pattern. The dishonesty findings — altered paperwork and claims about the verification of manually entered test results — were treated as the gravamen of the case, as they struck at the reliability of the safety checks on which the laboratory depends.

A central aggravating feature was timing. The panel found the errors and dishonesty occurred after a disciplinary process, re-training and being signed off as competent for full duties — meaning the conduct persisted even after his employer had given him a documented opportunity to correct it. The aggravating factors it listed were: no demonstration of insight or remediation; repeated dishonesty; a pattern of carelessness; the post-disciplinary, post-retraining timing; and risk of harm to patients. The panel found no insight or remediation and a real risk of repetition. On that basis it ordered striking off, with an interim suspension for up to 18 months to cover the appeal period or any appeal — a duration the determination expressly notes is not the substantive sanction.

Public Reaction and Consequences

The published record contains no press coverage of the hearing and no public statements — none from Pakha-Ephraim beyond his participation in the proceedings, and none from patients, colleagues or campaign groups. The concrete consequence is the striking-off order itself, together with the interim suspension that governs his registration status during the appeal period. MedicWatch, which maintains the practitioner-facing record of the decision, aggregates regulator outcomes and states it does not editorialise the regulator’s findings.

Current Status

Pakha-Ephraim is struck off the HCPC register. The striking-off order was imposed on 17 September 2026 at the close of the substantive hearing, with an interim suspension of up to 18 months covering the appeal period or any appeal before the substantive order takes effect. This followed the earlier interim suspension of 22 October 2024, which the Investigating Committee confirmed on 23 January 2026. His MedicWatch profile records erasure (struck off the register) on 17 September 2026 and directs readers to check the official HCPC register for current registration status. The published record shows no appeal and no application for restoration.

Impact on Their Career/Life

Striking off ends Pakha-Ephraim’s UK registration as a biomedical scientist unless a future restoration application succeeds, and the panel’s reasoning — repeated dishonesty, a collective pattern of carelessness, conduct continuing after re-training and sign-off as competent, and no insight or remediation — records why it found a real risk of repetition and no lesser sanction adequate. Biomedical scientist work in the UK is a protected title, so removal also bars use of the title in any laboratory role that requires HCPC registration. The published record contains no information about his circumstances beyond what is stated above, and nothing on this page should be read as going beyond it.

Sources

• *MedicWatch, “HCPTS orders Emmanuel Pakha-Ephraim to be struck off over misconduct findings” — source
• *MedicWatch, “Emmanuel Pakha-Ephraim — Interim restrictions imposed · 23 January 2026” — source
• *MedicWatch, “Emmanuel Pakha-Ephraim — Struck off the register | Health and Care Professions Council BS076762” — source